SYNDAX PHARMACEUTICALS INC (SNDX)
US87164F1057 - Common Stock
We assign a fundamental rating of 2 out of 10 to SNDX. SNDX was compared to 569 industry peers in the Biotechnology industry. SNDX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SNDX does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year SNDX has reported negative net income.
SNDX had a negative operating cash flow in the past year.
SNDX had negative earnings in 4 of the past 5 years.
SNDX had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
SNDX's Return On Assets of -69.76% is on the low side compared to the rest of the industry. SNDX is outperformed by 65.08% of its industry peers.
SNDX's Return On Equity of -81.07% is in line compared to the rest of the industry. SNDX outperforms 52.20% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -69.76% | ||
| ROE | -81.07% | ||
| ROIC | N/A |
ROA(3y)-19.55%
ROA(5y)-34.5%
ROE(3y)-21.21%
ROE(5y)-54.28%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SNDX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for SNDX has been increased compared to 1 year ago.
SNDX has more shares outstanding than it did 5 years ago.
SNDX has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 8.72 indicates that SNDX is not in any danger for bankruptcy at the moment.
SNDX's Altman-Z score of 8.72 is amongst the best of the industry. SNDX outperforms 84.83% of its industry peers.
SNDX has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
SNDX's Debt to Equity ratio of 0.00 is in line compared to the rest of the industry. SNDX outperforms 50.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 8.72 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 6.99 indicates that SNDX has no problem at all paying its short term obligations.
SNDX's Current ratio of 6.99 is fine compared to the rest of the industry. SNDX outperforms 68.08% of its industry peers.
A Quick Ratio of 6.99 indicates that SNDX has no problem at all paying its short term obligations.
With a decent Quick ratio value of 6.99, SNDX is doing good in the industry, outperforming 68.25% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.99 | ||
| Quick Ratio | 6.99 |
3. Growth
3.1 Past
SNDX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -40.70%.
EPS 1Y (TTM)-40.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-34.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 13.84% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-27.3%
EPS Next 2Y-11.85%
EPS Next 3Y4.97%
EPS Next 5Y13.84%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SNDX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SNDX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-11.85%
EPS Next 3Y4.97%
5. Dividend
5.1 Amount
SNDX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SYNDAX PHARMACEUTICALS INC
NASDAQ:SNDX (11/22/2024, 8:05:34 PM)
After market: 16.2499 +0.16 (+0.99%)16.09
+0.49 (+3.14%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.37B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -69.76% | ||
| ROE | -81.07% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.04
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 6.99 | ||
| Quick Ratio | 6.99 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-40.7%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-27.3%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y